FRANCE

EQS-News: Carbios will receive grants totaling €54 million from French State via France 2030 and Grand-Est Region

Retrieved on: 
Jeudi, juin 1, 2023
Plastic, Novozymes, Partnership, Euronext Growth, Civil service commission, PTA, European Commission–AstraZeneca COVID-19 vaccine dispute, INSA, University, Enzyme, PET, INRAE, Research, TBI, Recycling, Plant, Ministry of Ecological Transition (France), Grand Est, CNRS, TWB, MEG, Marshal of France, Region, Territory, Investment, Textile, Plastic recycling, FRANCE, Environment, News, Conference, European Commission, Tourism, Pharmaceutical industry, Renewable energy, Carbios, Metropolitan, Longlaville

Carbios selected for €30 million in funding from the French State via France 2030 and €12.5 million from the Grand-Est Region, subject to ratification by the European Commission, for the construction of Carbios' first industrial plant in Longlaville (54).

Key Points: 
  • Carbios selected for €30 million in funding from the French State via France 2030 and €12.5 million from the Grand-Est Region, subject to ratification by the European Commission, for the construction of Carbios' first industrial plant in Longlaville (54).
  • The reference plant in Longlaville in the Grand-Est region will be the world’s first PET biorecycling plant and is due for commissioning in 2025.
  • This funding will enable to continue its research into the optimization and continuous improvement of Carbios’ enzymatic technologies.
  • They have spared no effort, with the constant support of the French State and ADEME, to make this plant a reality.

Carbios Will Receive Grants Totaling €54 Million From French State via France 2030 and Grand-Est Region1 to Finance Construction of World's First PET Biorecycling Plant and Accelerate R&D Activities

Retrieved on: 
Mercredi, mai 31, 2023
Biotechnology, Sustainability, Environment, Health, Recycling, Chemicals, Plastics, Green Technology, Manufacturing, Plastic, Partnership, PTA, European Commission–AstraZeneca COVID-19 vaccine dispute, University, Enzyme, PET, MEG3, Multimedia, Research, Plant, Ministry of Ecological Transition (France), Grand Est, Marshal of France, Region, Territory, Investment, Textile, Plastic recycling, FRANCE, News, Conference, European Commission, Renewable energy, Pharmaceutical industry, Carbios, Metropolitan, Longlaville

The reference plant in Longlaville in the Grand-Est region will be the world’s first PET biorecycling plant and is due for commissioning in 2025.

Key Points: 
  • The reference plant in Longlaville in the Grand-Est region will be the world’s first PET biorecycling plant and is due for commissioning in 2025.
  • This plant will make it possible to relocate to France the production of the two basic components of PET, PTA and MEG3, both derived from the Carbios process.
  • For many years, French public and private research teams have been working together to develop a new enzymatic recycling technology.
  • They have spared no effort, with the constant support of the French State and ADEME, to make this plant a reality.

EQS-News: Andera Partners co-leads $25m extension round for FIRE1, an Irish medtech developing breakthrough technology for patients with heart failure

Retrieved on: 
Jeudi, mars 16, 2023
Hospital, FRANCE, Heart failure, Partner, Patient, Novo Holdings A/S, Pharmaceutical industry

Andera Partners co-leads $25m extension round for FIRE1, an Irish medtech developing breakthrough technology for patients with heart failure

Key Points: 
  • Andera Partners co-leads $25m extension round for FIRE1, an Irish medtech developing breakthrough technology for patients with heart failure
    The issuer is solely responsible for the content of this announcement.
  • Andera Partners co-leads $25m extension round for FIRE1, an Irish medtech developing breakthrough technology for patients with heart failure
    PARIS, FRANCE – MARCH 15, 2023 – Andera Partners, a leading European private equity player, today announces a $25m extension round, co-led with Novo Holdings, for Irish medtech company, FIRE1 Ltd.
  • The financing provides FIRE1 with capital to accelerate the development of its novel remote monitoring solution to improve outcomes for heart failure patients.
  • “Heart failure affects over 60 million patients worldwide and is the leading cause of hospitalization in patients over 65.

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Retrieved on: 
Lundi, février 13, 2023
Science, ADR, Kidney cancer, Checkmate, CR, Immunotherapy, Abstract, FRANCE, Rescue coordination centre, Medicine, Patient, Classification, IPN, Risk, Survival rate, Doctor of Philosophy, ORR, Survival, Phase, Progression-free survival, Society, Dor, PFS, IMDC, Cancer, RCC, Nivolumab, ASCO, Pharmaceutical industry, OS, Cabozantinib, Euronext

“With these updated results from CheckMate -9ER, we’ve now seen nivolumab in combination with cabozantinib durably extend survival and sustain response benefits compared to sunitinib for over three years, regardless of patients’ risk classification.

Key Points: 
  • “With these updated results from CheckMate -9ER, we’ve now seen nivolumab in combination with cabozantinib durably extend survival and sustain response benefits compared to sunitinib for over three years, regardless of patients’ risk classification.
  • Responses also continued to be more durable with the combination, with a median DoR (duration of response) of 23.1 months compared to 15.2 months with sunitinib.
  • Results were also assessed by the following International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk scores: favorable, intermediate, intermediate/poor and poor.
  • These include:
    The CaboCombo trial, which is a prospective, international, non-interventional study of first-line Cabometyx plus nivolumab for the treatment of patients with aRCC.

GENFIT Reports Third Quarter 2022 Financial Information

Retrieved on: 
Jeudi, novembre 10, 2022
Review, Private Securities Litigation Reform Act, Business, Nasdaq, NASH, Research, Loos, Institute of Liver and Biliary Sciences, LabCorp, COVID-19, United Kingdom, PBC, SEC, Annual report, Safety, U.S. Securities and Exchange Commission, Cholangiocarcinoma, Cirrhosis, FRANCE, Biomarker, Company, Ipsen, Chapter Two, Patient, Primary biliary cholangitis, Industry, AMF, History, Acquisition, Chronic liver disease, Income, Animal, Pharmaceutical industry, Euronext, ACLF

As of September 30, 2022, the Companys cash and cash equivalents amounted to 163.6 million compared with 91.5 million a year earlier.

Key Points: 
  • As of September 30, 2022, the Companys cash and cash equivalents amounted to 163.6 million compared with 91.5 million a year earlier.
  • The decrease in cash and cash equivalents between June 30, 2022, and September 30, 2022, takes into account notably the initial consideration of CHF40.0 million for the acquisition of Versantis AG, which GENFIT paid at the closing of this acquisition on September 29, 2022.
  • Revenue2 for the first nine months of 2022 amounted to 14,129 thousand compared to 20 thousand for the same period in 2021.
  • The revenue recognized out of this deferred income amounted to 13,050 thousand for the first nine months of 2022.

GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis

Retrieved on: 
Jeudi, septembre 29, 2022
Nasdaq, Safety, COVID-19, Primary biliary cholangitis, Loos, Cholangiocarcinoma, Biomarker, Institute of Liver and Biliary Sciences, FRANCE, NASH, U.S. Securities and Exchange Commission, Liver disease, Company, Acquisition, Review, Private Securities Litigation Reform Act, Industry, Business, Patient, History, United Kingdom, Chronic liver disease, Annual report, Financial assistance (share purchase), Professor, LabCorp, Doctor of Philosophy, Board, ETH Zurich, Chapter Two, AMF, Cirrhosis, PBC, Research, SEC, Medical imaging, Pharmaceutical industry, ACLF, Euronext

GENFIT will also further expand its pipeline in other liver diseases characterized by high unmet medical needs with additional product candidates developed by Versantis.

Key Points: 
  • GENFIT will also further expand its pipeline in other liver diseases characterized by high unmet medical needs with additional product candidates developed by Versantis.
  • GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs.
  • GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades.
  • The company is headquartered in Zurich, Switzerland, with an established wholly-owned U.S. subsidiary, Versantis, Inc. For additional information, visit: www.versantis.com.

FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Retrieved on: 
Mardi, septembre 13, 2022
Nasdaq, Safety, Industry, Patient, U.S. Securities and Exchange Commission, United Kingdom, Research, Disease, Palmitoyl(protein) hydrolase, Probability, COVID-19, Food, Company, Acquisition, History, Primary sclerosing cholangitis, Annual report, Chapter Two, Associate, AMF, SEC, Mortality, FDA, Loos, NASH, Hope, Liver disease, Review, Lysosome, Cirrhosis, Hepatolithiasis, Johns Hopkins University, Autophagy, Primary biliary cholangitis, Biomarker, FRANCE, Private Securities Litigation Reform Act, Bile, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Cancer, Chronic liver disease, LabCorp, PBC, Pharmaceutical industry, Medical imaging, ACLF, Cholangiocarcinoma, Oncology, Euronext

GNS561 has completed pre-clinical studies and a Phase 1b trial confirming the rationale for targeting cholangiocarcinoma.

Key Points: 
  • GNS561 has completed pre-clinical studies and a Phase 1b trial confirming the rationale for targeting cholangiocarcinoma.
  • Dr Mark Yarchoan, Associate Professor of Oncology at John Hopkins Medicine (Baltimore, MD) commented: Cholangiocarcinoma is a rare cancer with a high mortality rate.
  • This is why new therapies are urgently needed and is one of the reasons that GNS561 was granted Orphan Drug Designation by the FDA.
  • There is a real path forward for new options for second line treatment in cholangiocarcinoma, and GNS561 represents a strong second-line therapy candidate and hope to patients.

GENFIT: May 25, 2022 Combined Shareholders Meeting results

Retrieved on: 
Mercredi, mai 25, 2022
U.S. Securities and Exchange Commission, Roger W. Jones Award for Executive Leadership, Company, History, Private Securities Litigation Reform Act, NASH, FRANCE, Nasdaq, Doctor of Philosophy, Director, Patient, AMF, PBC, Review, Chapter Two, Research, United Kingdom, Cholangiocarcinoma, Industry, Partnership, Liver disease, Primary biliary cholangitis, Board, Safety, Biomarker, Board of directors, Loos, Cirrhosis, LabCorp, SEC, Acquisition, Chronic liver disease, Annual report, Management, Pharmaceutical industry, Euronext, Pharmacovigilance, ACLF, Ipsen

The quorum on first convening amounted to 25.16% and shareholders approved all of the resolutions submitted by the Board of Directors.

Key Points: 
  • The quorum on first convening amounted to 25.16% and shareholders approved all of the resolutions submitted by the Board of Directors.
  • Jean-Franois Mouney, Chairman of GENFITs Board of Directors, commented: I would like to thank all of our shareholders who participated in this Combined Shareholders Meeting.
  • This appointment is in keeping with the long-term strategic partnership agreement signed with Ipsen at the end of 2021.
  • In ACLF, a Phase 1 clinical program with nitazoxanide has been initiated with data expected as early as the third quarter 2022.

Dialysis Equipment Market Research Report 2022: Synthetic High-flux Membranes and Unmodified Cellulose Low-flux Membranes - Global Forecast to 2027 - Increasing Demand For Peritoneal Dialysis Devices - ResearchAndMarkets.com

Retrieved on: 
Lundi, mai 23, 2022
Medical Devices, Health, BLOOD, USD, SINGAPORE, ARAB, CANADA, FRANCE, ITALY, NETHERLANDS, AMERICAS, BY, DOLLAR, GERMANY, CHINA, AFRICA, INDIA, RESEARCH, TYPE, DRUG, SALT, COUNTRY, MALAYSIA, Medical device, Lithium, Bank, Aquaculture, Cosmetics, Telecommunication, Retail, Video game, Foodservice, Fine chemical, Coal, Software, Film, Cryptocurrency, Weapon, Flowers, Gum arabic, Coffee, Rare-earth element, EUROPE

GLOBAL DIALYSIS EQUIPMENT MARKET SIZE, BY UNMODIFIED CELLULOSE LOW-FLUX MEMBRANES, 2019-2027 (USD BILLION)

Key Points: 
  • GLOBAL DIALYSIS EQUIPMENT MARKET SIZE, BY UNMODIFIED CELLULOSE LOW-FLUX MEMBRANES, 2019-2027 (USD BILLION)
    FIGURE 8.
  • GLOBAL DIALYSIS EQUIPMENT MARKET SIZE, BY UNMODIFIED CELLULOSE LOW-FLUX MEMBRANES, BY REGION, 2021 VS 2027 (USD BILLION)
    FIGURE 9.
  • GLOBAL DIALYSIS EQUIPMENT MARKET SIZE, BY DIALYSIS CENTERS, 2019-2027 (USD BILLION)
    FIGURE 26.
  • GLOBAL DIALYSIS EQUIPMENT MARKET SIZE, BY UNMODIFIED CELLULOSE LOW-FLUX MEMBRANES, BY REGION, 2019-2027 (USD BILLION)
    TABLE 10.

GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)

Retrieved on: 
Mercredi, mai 11, 2022
Company, History, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, NASH, FRANCE, Nasdaq, Patient, AMF, PBC, Review, Chapter Two, Research, United Kingdom, Cholangiocarcinoma, Industry, Partnership, Liver disease, Primary biliary cholangitis, Safety, Biomarker, Loos, IFRS, Cirrhosis, LabCorp, SEC, Acquisition, Chronic liver disease, Annual report, Online gambling, Cryptocurrency, Security (finance), Pharmaceutical industry, Euronext, VAT, ACLF, Ipsen

Furthermore, to underscore the long-term commitment represented by this partnership, Ipsen purchased newly issued GENFIT equity representing 8% post-issuance through a 28.0 million investment in GENFIT.

Key Points: 
  • Furthermore, to underscore the long-term commitment represented by this partnership, Ipsen purchased newly issued GENFIT equity representing 8% post-issuance through a 28.0 million investment in GENFIT.
  • Revenues for the first three months of 2022 amounted to 3.895 million compared to 1 thousand for the same period in 2021.
  • Revenues for the first three months of 2022 mainly came from the partial recognition of this amount corresponding to this period.
  • In ACLF, a Phase 1 clinical program with nitazoxanide has been initiated with data expected as early as the third quarter 2022.